Spirax Group
Search results
Smith+Nephew is a portfolio medical technology company focused on the repair, regeneration and replacement of soft and hard tissue. We exist to restore people's bodies and their self-belief by using technology to take the limits off living.
Home Health Care Professionals. Products. Find a Product. Search below to find key information and resources on the purpose, benefits and application of our products and solutions, depending on your healthcare needs.
Smith+Nephew is a portfolio medical device company focused on the repair, regeneration and replacement of soft and hard tissue.
Find out more about careers and culture at Smith+Nephew, including inclusion, diversity and equity, wellbeing, flexibility and benefits, and our current vacancies.
この度、スミス・アンド・ネフューのウェブサイトを大幅にリニューアルいたしました。. 今回のリニューアルでは、お客様がより使いやすいようにデザインや構成を見直し、機能の追加をいたしました。. リニューアルにともない、URLが変更になりましたの ...
Smith+Nephew Academy On-demand medical education and events Explore Products Indication-specific solutions and associated guidance Explore Procedures, Indications and Therapies Find suitable information and solutions for a specific procedure, aetiology or indication, including treatment pathways or products, relevant patient information and related healthcare considerations Explore Support ...
Product enquiries For questions about Smith+Nephew products or treatments. Note: this form is intended for healthcare professionals only.
PICO Single Use Negative Pressure Wound Therapy System. Features proprietary AIRLOCK Technology and has shown clinical efficacy in the treatment of closed surgical incisions and hard-to-heal wounds, with patient-centric features and the capacity to treat two incisions on the same patient from one device (depending on system choice)* 1-10.
United States of America. Smith & Nephew, Inc. 150 Minuteman Road Andover, Massachusetts 01810 USA Tel: +1 (978) 749 1000 Fax: +1 (978) 749 1599. Website :
Feb 21, 2023 · Our fourth quarter revenue was $1,365 million (2021: $1,346 million), up 6.8% on an underlying basis (reported revenue growth of 1.4% after 540bps foreign exchange headwind). There were the same number of trading days as in the comparable period (2022: 60 trading days).
